Resisting Lung Cancer Recurrence: Vaccine Booster Gives Persistent Immune Response
What if we could prevent cancer recurrence for years after surgery by giving simple recall injections every two or three years? This concept may no longer be a fantasy. In a clinical study a team headed by the international Ludwig Institute for Cancer Research (LICR) has shown that a vaccine against a protein found in cancer cells produces an immune response that can be boosted and strengthened with additional vaccine shots. Patients with resected non-small cell lung cancer (NSCLC) were treated with this investigational agent, also known as an Antigen-Specific Cancer Immunotherapeutic (ASCI), in another clinical study conducted by GlaxoSmithKline.
This entry was posted on Wednesday, February 6th, 2008 at 11:18 am and is filed under Research, Non-Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.